CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel therapeutic strategies.

Successful applicants will receive up to $200k p.a. for up to 2 years (max $400k funding). Interested researchers are invited to contact their Technology Transfer/Commercialization office for information session webinar links and online application instructions. Researchers who wish to apply are required to submit a 300 word online abstract by 28th February 2022.

The 2022 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area and are amenable to or include a Modality as illustrated below. Please see over page for specific Focus Areas.

For webinar links and online application instructions please contact your Technology Transfer / Commercialization office.
CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications that align with a CSL Therapeutic Area and are amenable to or include a CSL Modality in the following Focus Areas:

**Immunology**
- **Immune deficiencies**
  - PID gene therapy and targets
- **Autoimmune diseases (AIDs)**
  - (e.g. primary Sjögren's syndrome; systemic sclerosis; idiopathic myositis incl. dermatomyositis, polymyositis and others; and autoimmune blistering diseases)
- **Therapeutic strategies for AIDs**
  - Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
  - B cell depletion / regulation strategies
- **Alternatives to plasma-derived immunoglobulin / Recombinant IVig**

**Hematology**
- **Hemorrhagic stroke**
  - Novel biologic targets / therapeutics or strategies to understand pathomechanisms
- **Acute thrombosis**
  - (pulmonary embolism, acute ischemic stroke)
  - Novel therapies and approaches for targeted fibrinolysis / thrombolysis with increased efficacy and safety
- **Sickle cell disease**
  - Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy
  - Biomarker / Omics approaches for patient stratification and drug discovery for above indications

**Respiratory**
- **Idiopathic pulmonary fibrosis (IPF) and other chronic, progressive fibrosing interstitial lung diseases (ILD)**
- **Community acquired pneumonia (CAP)- associated complications**
  - (acute respiratory distress syndrome (ARDS), sepsis, acute kidney injury)
  - Therapeutic biologics and Omics approaches for patient stratification and drug discovery for above indications

**Cardiovascular & Metabolic**
- **Myocarditis / Inflammatory cardiomyopathy**
- **Rare lipid disorders**
  - (e.g. familial hypercholesterolemia, familial chylomicronemia)
  - **Severe forms of atherosclerosis**

**Transplant**
- **Chronic lung allograft dysfunction (CLAD)**
  - Novel biologic targets / therapeutics for prevention of CLAD
- **Tolerance**
  - Novel biologic targets / therapeutics for immunomodulation and tolerance induction in SOT and HSCT incl. strategies to expand Tregs in vivo
- **Hematopoietic stem cell transplants (HSCT)**
  - Novel biologic targets / therapeutics for improving efficacy / safety
  - **Chronic GvHD**
    - Novel biologic targets / therapeutics for treatment and prevention

**Cardiovascular allograft vasculopathy**
- Novel biologic targets / therapeutics for treatment and prevention

**Gene Therapy**
- **Non-viral in vivo delivery of gene editing RNPs**
  - Lipid nanoparticle (LNP) or polymer-based
- **Modulation of transgene expression in vivo**
  - Technologies that may be able to tune the expression of a transgene delivered by lentiviral gene therapy
- **Universal HDR enhancers to improve gene editing efficiency**
  - Methods or molecules that may enhance gene insertion
- **Improved HSC transduction methods**
  - Chemically or physically to enhance transduction of lentiviral vectors on HSCs
- **LV production improvements**
  - Yield and/or quality of lentivirus production

**Oral delivery**
- **Technologies enabling oral delivery of biologics**
  - (e.g. antibodies and other protein therapeutics)

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail rai@csl.com.au to discuss.